Illumina, Inc. (ILMN)
USD 134.03
(-6.35%)
USD 134.03
(-6.35%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.81 Billion USD | 7.72% |
| 2022 | 2.61 Billion USD | -20.11% |
| 2021 | 3.27 Billion USD | 101.91% |
| 2020 | 1.62 Billion USD | 9.51% |
| 2019 | 1.48 Billion USD | 4.59% |
| 2018 | 1.41 Billion USD | 16.15% |
| 2017 | 1.22 Billion USD | 12.19% |
| 2016 | 1.08 Billion USD | 17.41% |
| 2015 | 926.18 Million USD | 8.41% |
| 2014 | 854.33 Million USD | 29.88% |
| 2013 | 657.78 Million USD | 27.23% |
| 2012 | 517.01 Million USD | 3.28% |
| 2011 | 500.58 Million USD | 28.39% |
| 2010 | 389.88 Million USD | 20.47% |
| 2009 | 323.63 Million USD | 23.3% |
| 2008 | 262.48 Million USD | 13.06% |
| 2007 | 232.17 Million USD | 165.55% |
| 2006 | 87.43 Million USD | 56.22% |
| 2005 | 55.96 Million USD | 30.65% |
| 2004 | 42.83 Million USD | -4.0% |
| 2003 | 44.62 Million USD | -7.73% |
| 2002 | 48.35 Million USD | 49.96% |
| 2001 | 32.24 Million USD | 29.29% |
| 2000 | 24.94 Million USD | 284.4% |
| 1999 | 6.48 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 492 Million USD | 107.59% |
| 2024 Q1 | 726 Million USD | -0.82% |
| 2024 Q2 | 237 Million USD | -67.36% |
| 2023 Q2 | 808 Million USD | 12.38% |
| 2023 Q1 | 719 Million USD | -7.58% |
| 2023 FY | 2.82 Billion USD | 7.72% |
| 2023 Q4 | 732 Million USD | 18.45% |
| 2023 Q3 | 618 Million USD | -23.51% |
| 2022 FY | 2.61 Billion USD | -20.11% |
| 2022 Q4 | 778 Million USD | 65.18% |
| 2022 Q3 | 471 Million USD | -36.09% |
| 2022 Q2 | 737 Million USD | 16.8% |
| 2022 Q1 | 631 Million USD | -18.69% |
| 2021 Q1 | 571 Million USD | 14.66% |
| 2021 Q2 | 615 Million USD | 7.71% |
| 2021 Q4 | 776 Million USD | -40.99% |
| 2021 Q3 | 1.31 Billion USD | 113.82% |
| 2021 FY | 3.27 Billion USD | 101.91% |
| 2020 Q3 | 364 Million USD | 9.64% |
| 2020 Q4 | 498 Million USD | 36.81% |
| 2020 FY | 1.62 Billion USD | 9.51% |
| 2020 Q1 | 430 Million USD | 9.14% |
| 2020 Q2 | 332 Million USD | -22.79% |
| 2019 Q4 | 394 Million USD | 15.88% |
| 2019 FY | 1.48 Billion USD | 4.59% |
| 2019 Q1 | 380 Million USD | -3.31% |
| 2019 Q2 | 368 Million USD | -3.16% |
| 2019 Q3 | 340 Million USD | -7.61% |
| 2018 FY | 1.41 Billion USD | 16.15% |
| 2018 Q1 | 320 Million USD | 2.56% |
| 2018 Q2 | 348 Million USD | 8.75% |
| 2018 Q3 | 356 Million USD | 2.3% |
| 2018 Q4 | 393 Million USD | 10.39% |
| 2017 Q1 | 308 Million USD | 11.59% |
| 2017 FY | 1.22 Billion USD | 12.19% |
| 2017 Q4 | 312 Million USD | 3.65% |
| 2017 Q3 | 301 Million USD | 0.67% |
| 2017 Q2 | 299 Million USD | -2.92% |
| 2016 FY | 1.08 Billion USD | 17.41% |
| 2016 Q4 | 276 Million USD | 4.13% |
| 2016 Q1 | 273.22 Million USD | 4.45% |
| 2016 Q3 | 265.06 Million USD | -2.95% |
| 2016 Q2 | 273.12 Million USD | -0.04% |
| 2015 Q1 | 208.08 Million USD | -21.51% |
| 2015 Q4 | 261.59 Million USD | 10.91% |
| 2015 Q2 | 220.62 Million USD | 6.02% |
| 2015 Q3 | 235.87 Million USD | 6.91% |
| 2015 FY | 926.18 Million USD | 8.41% |
| 2014 Q4 | 265.12 Million USD | 29.35% |
| 2014 Q3 | 204.97 Million USD | 3.71% |
| 2014 Q2 | 197.63 Million USD | 5.91% |
| 2014 Q1 | 186.61 Million USD | -0.94% |
| 2014 FY | 854.33 Million USD | 29.88% |
| 2013 FY | 657.78 Million USD | 27.23% |
| 2013 Q4 | 188.37 Million USD | 13.09% |
| 2013 Q3 | 166.57 Million USD | 6.57% |
| 2013 Q2 | 156.3 Million USD | 6.68% |
| 2013 Q1 | 146.52 Million USD | 7.25% |
| 2012 Q4 | 136.62 Million USD | -7.24% |
| 2012 Q1 | 127.04 Million USD | -7.05% |
| 2012 Q3 | 147.27 Million USD | -0.66% |
| 2012 FY | 517.01 Million USD | 3.28% |
| 2012 Q2 | 148.26 Million USD | 16.71% |
| 2011 Q2 | 122.57 Million USD | 3.31% |
| 2011 Q1 | 118.65 Million USD | 11.32% |
| 2011 FY | 500.58 Million USD | 28.39% |
| 2011 Q4 | 136.67 Million USD | 11.16% |
| 2011 Q3 | 122.94 Million USD | 0.3% |
| 2010 FY | 389.88 Million USD | 20.47% |
| 2010 Q2 | 97.33 Million USD | 3.6% |
| 2010 Q3 | 99.81 Million USD | 2.54% |
| 2010 Q1 | 93.95 Million USD | 2.67% |
| 2010 Q4 | 106.58 Million USD | 6.79% |
| 2009 FY | 323.63 Million USD | 23.3% |
| 2009 Q1 | 77.22 Million USD | 10.01% |
| 2009 Q2 | 76.72 Million USD | -0.65% |
| 2009 Q4 | 91.5 Million USD | 17.06% |
| 2009 Q3 | 78.17 Million USD | 1.88% |
| 2008 FY | 262.48 Million USD | 13.06% |
| 2008 Q4 | 70.19 Million USD | 0.81% |
| 2008 Q3 | 69.63 Million USD | 5.75% |
| 2008 Q2 | 65.84 Million USD | 15.92% |
| 2008 Q1 | 56.8 Million USD | -46.04% |
| 2007 Q2 | 42.14 Million USD | 5.28% |
| 2007 Q1 | 40.03 Million USD | 68.62% |
| 2007 FY | 232.17 Million USD | 165.55% |
| 2007 Q4 | 105.27 Million USD | 135.4% |
| 2007 Q3 | 44.72 Million USD | 6.12% |
| 2006 Q4 | 23.74 Million USD | 8.59% |
| 2006 FY | 87.43 Million USD | 56.22% |
| 2006 Q1 | 20.35 Million USD | 29.22% |
| 2006 Q2 | 21.47 Million USD | 5.54% |
| 2006 Q3 | 21.86 Million USD | 1.79% |
| 2005 FY | 55.96 Million USD | 30.65% |
| 2005 Q2 | 13.83 Million USD | 16.0% |
| 2005 Q3 | 14.45 Million USD | 4.47% |
| 2005 Q4 | 15.74 Million USD | 8.95% |
| 2005 Q1 | 11.92 Million USD | 51.2% |
| 2004 Q2 | 11.75 Million USD | 2.9% |
| 2004 Q4 | 7.88 Million USD | -33.0% |
| 2004 Q3 | 11.77 Million USD | 0.2% |
| 2004 Q1 | 11.42 Million USD | 2.72% |
| 2004 FY | 42.83 Million USD | -4.0% |
| 2003 Q2 | 11.23 Million USD | -1.07% |
| 2003 Q3 | 10.91 Million USD | -2.89% |
| 2003 Q4 | 11.11 Million USD | 1.92% |
| 2003 Q1 | 11.35 Million USD | -86.5% |
| 2003 FY | 44.62 Million USD | -7.73% |
| 2002 Q2 | 18.13 Million USD | 82.11% |
| 2002 Q4 | 84.13 Million USD | 1036.81% |
| 2002 Q3 | -8.98 Million USD | -149.52% |
| 2002 Q1 | 9.95 Million USD | 5.72% |
| 2002 FY | 48.35 Million USD | 49.96% |
| 2001 FY | 32.24 Million USD | 29.29% |
| 2001 Q3 | 7.77 Million USD | -1.45% |
| 2001 Q2 | 7.88 Million USD | 8.86% |
| 2001 Q1 | 7.24 Million USD | -2.09% |
| 2001 Q4 | 9.42 Million USD | 21.24% |
| 2000 Q3 | 6.21 Million USD | 5.3% |
| 2000 Q4 | 7.39 Million USD | 18.95% |
| 2000 Q1 | 5.42 Million USD | 0.0% |
| 2000 FY | 24.94 Million USD | 284.4% |
| 2000 Q2 | 5.9 Million USD | 8.93% |
| 1999 FY | 6.48 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | -2459.181% |
| Prenetics Global Limited | 60.73 Million USD | -6177.927% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -23332.891% |
| CareDx, Inc | 277.76 Million USD | -1272.728% |
| Exact Sciences Corporation | 2.06 Billion USD | -85.049% |
| Exagen Inc. | 52.29 Million USD | -7191.607% |
| Inotiv, Inc. | 246.9 Million USD | -1444.331% |
| Guardant Health, Inc. | 901.62 Million USD | -322.905% |
| Biodesix, Inc. | 77.41 Million USD | -4825.148% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -97093.893% |
| Precipio, Inc. | 13.63 Million USD | -27858.645% |
| iSpecimen Inc. | 16.27 Million USD | -23325.311% |
| Natera, Inc. | 938.98 Million USD | -306.077% |
| Aspira Women's Health Inc. | 24.11 Million USD | -15712.391% |
| Standard BioTools Inc. | 113.48 Million USD | -3259.797% |
| 23andMe Holding Co. | 420.73 Million USD | -806.275% |
| Castle Biosciences, Inc. | 242.78 Million USD | -1470.538% |
| Personalis, Inc. | 128.14 Million USD | -2875.559% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | -3349.898% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -23027.702% |
| OpGen, Inc. | 30.65 Million USD | -12337.226% |
| T2 Biosystems, Inc. | 41.49 Million USD | -9089.28% |
| Myriad Genetics, Inc. | 600.1 Million USD | -535.394% |
| ICON Public Limited Company | 755.64 Million USD | -404.603% |
| NeoGenomics, Inc. | 341.25 Million USD | -1017.356% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -23332.891% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | -248.907% |
| RadNet, Inc. | 268.87 Million USD | -1318.11% |
| MDxHealth SA | 71.25 Million USD | -5251.128% |
| Psychemedics Corporation | 11.33 Million USD | -33542.139% |
| Check-Cap Ltd. | 19.28 Million USD | -19669.793% |
| Twist Bioscience Corporation | 354.18 Million USD | -976.571% |
| DarioHealth Corp. | 62.17 Million USD | -6032.887% |
| Fulgent Genetics, Inc. | 171.9 Million USD | -2118.073% |
| Sera Prognostics, Inc. | 39.91 Million USD | -9452.321% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -36142.715% |
| OPKO Health, Inc. | 574.68 Million USD | -563.493% |
| Medpace Holdings, Inc. | 187.68 Million USD | -1931.65% |
| Neogen Corporation | 405.23 Million USD | -840.931% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -32465.25% |
| Prenetics Global Limited | 60.73 Million USD | -6177.927% |
| Mainz Biomed B.V. | 27.15 Million USD | -13941.954% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -43403.346% |
| Trinity Biotech plc | 46.49 Million USD | -8100.882% |
| Neuronetics, Inc. | 82.25 Million USD | -4535.359% |
| Sotera Health Company | 300.46 Million USD | -1169.029% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -43403.346% |